ArticleProceedings of the National Academy of Sciences of the United States of America2016
Immune cell screening of a nanoparticle library improves atherosclerosis therapy.
Open access · bronzeAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.
- A bibliometric analysis of immunotherapy for atherosclerosis: trends and hotspots prediction.Frontiers in immunology · 2024Pooled it
- Graphene Nanoplatelets Suppress Foam Cell Formation and Atherogenic Inflammation in Macrophages.Cellular and molecular bioengineering · 2026Article
- A high-throughput approach to optimize and understand nanoparticle protein degraders.Nanoscale advances · 2026Article
- Radiolabeling lipoproteins to study and manage disease.European journal of nuclear medicine and molecular imaging · 2025Review
- High-Density Lipoprotein Biomimetic Inorganic-Organic Composite Nanosystem for Atherosclerosis Therapy.Polymers · 2025Article
- Nuclear Nanomedicines: Utilization of Radiolabelling Strategies, Drug Formulation, Delivery, and Regulatory Aspects for Disease Management.Current radiopharmaceuticals · 2025Review
- Influence of cell bioenergetics on host-pathogen interaction in the lung.Frontiers in immunology · 2025Review
- Emerging nanoprobes for the features visualization of vulnerable atherosclerotic plaques.Smart medicine · 2024Review
- Macrophage polarization and metabolic reprogramming in abdominal aortic aneurysm.Immunity, inflammation and disease · 2024Review
- Application of Photodynamic Therapy in Cardiology.International journal of molecular sciences · 2024Review
- Nanoparticles as a Novel Platform for Cardiovascular Disease Diagnosis and Therapy.International journal of nanomedicine · 2024Review
- Nanomedicine for Diagnosis and Treatment of Atherosclerosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- New Opportunities and Old Challenges in the Clinical translation of Nanotheranostics.Nature reviews. Materials · 2023Article
- Biomimetic nanomedicines for precise atherosclerosis theranostics.Acta pharmaceutica Sinica. B · 2023Review
- Nanotechnologies meeting natural sources: Engineered lipoproteins for precise brain disease theranostics.Asian journal of pharmaceutical sciences · 2023Review
- Nanomedicines for cardiovascular disease.Nature cardiovascular research · 2023Review
- Targeting macrophages in atherosclerosis using nanocarriers loaded with liver X receptor agonists: A narrow review.Frontiers in molecular biosciences · 2023Review
- Radiolabeled nanomaterial for cancer diagnostics and therapeutics: principles and concepts.Cancer nanotechnology · 2023Review
- Tuning macrophages for atherosclerosis treatment.Regenerative biomaterials · 2023Review
- Methods for Radiolabelling Nanoparticles: PET Use (Part 2).Biomolecules · 2022Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 8 institutions in 2 countries.
Jun TangTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY 10029.ORCID 0000-0002-8285-5111
Samantha BaxterTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY 10029.
Arjun MenonDivision of Cardiology, Department of Medicine, Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, 550 First Avenue, New York, NY 10016.
Amr AlaargTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY 10029.
Brenda L Sanchez-GaytanTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY 10029.
Francois FayTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY 10029.
Yiming ZhaoTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY 10029.
Mireille OuimetDivision of Cardiology, Department of Medicine, Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, 550 First Avenue, New York, NY 10016.
Mounia S BrazaTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY 10029.
Valerie A LongoSmall-Animal Imaging Core Facility, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065.
Dalya Abdel-AttiDepartment of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065.
Raphael DuivenvoordenTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY 10029.
Claudia CalcagnoTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY 10029.
Gert StormDepartment of Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, 7500 AE Enschede, The Netherlands.
Sotirios TsimikasSulpizio Cardiovascular Center, Department of Medicine, University of California, San Diego, 9434 Medical Center Drive, La Jolla, CA 92037.
Kathryn J MooreDivision of Cardiology, Department of Medicine, Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, 550 First Avenue, New York, NY 10016.
Filip K SwirskiCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Simches Research Building, 185 Cambridge Street, Boston, MA 02114.
Matthias NahrendorfCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Simches Research Building, 185 Cambridge Street, Boston, MA 02114.
Edward A FisherDivision of Cardiology, Department of Medicine, Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, 550 First Avenue, New York, NY 10016.
Carlos Pérez-MedinaTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY 10029.
Zahi A FayadTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY 10029.
Thomas ReinerDepartment of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065.
Willem J M MulderTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY 10029; Willem.mulder@mssm.edu.
Icahn School of Medicine at Mount Sinai · USMemorial Sloan Kettering Cancer Center · USNew York University · USHarvard University · USAmsterdam UMC Location University of Amsterdam · NLUniversity of California San Diego · USUniversity of Twente · NLUtrecht University · NL
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTranslational imaging and nanomedicine in inflammatory atherosclerosisP01HL131478 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Abraham Teunissen · 2017 to 2026
$24.3MTraining Program in Cardiovascular SciencesT32HL098129 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Glenn I Fishman, Ira J Goldberg · 2009 to 2026
$5.9MTheranostic HDL nanoparticles for inflammatory macrophages in atherosclerosisR01EB009638 · NIBIB · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FAYAD, ZAHI A. · 2009 to 2016
$4.6MMonocyte Heterogeneity in Experimental and Human AtherosclerosisR01HL095612 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI SWIRSKI, FILIP K · 2009 to 2016
$3.4MLifestyle effects on hematopoiesis and atherosclerosisR01HL128264 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI NAHRENDORF, MATTHIAS, SWIRSKI, FILIP K · 2015 to 2018
$3.3MPET/MRI to study nanotherapy in atherosclerosisR01HL125703 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MULDER, WILLEM · 2015 to 2018
$2.4MAnti-inflammatory nanoparticle formulations to treat atherosclerosisR01HL118440 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MULDER, WILLEM, NAHRENDORF, MATTHIAS · 2014 to 2017
$2.3MA Surface Activable Nanoemulsion platform for Breast Cancer Diagnosis and TherapyR01CA155432 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MULDER, WILLEM · 2011 to 2015
$1.7MBioorthogonal Strategies for Targeted PET Imaging Probe DevelopmentK25EB016673 · NIBIB · SLOAN-KETTERING INST CAN RESEARCH · PI REINER, THOMAS · 2013 to 2015
$525kDiscovery and Prediction of Novel Functional Outcome Phenotypes for ARDSR21HL123433 · NHLBI · IHC HEALTH SERVICES, INC. · PI BROWN, SAMUEL MORRIS, NEEDHAM, DALE MURRAY · 2014 to 2015
$217kNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA155432NHLBI NIH HHS P01 HL131478NHLBI NIH HHS R01 HL095612NHLBI NIH HHS R01 HL118440NHLBI NIH HHS R01 HL125703NHLBI NIH HHS R01 HL128264NHLBI NIH HHS R21 HL123433NHLBI NIH HHS T32 HL098129NIBIB NIH HHS K25 EB016673NIBIB NIH HHS R01 EB009638
Abstract
Immunological complexity in atherosclerosis warrants targeted treatment of specific inflammatory cells that aggravate the disease. With the initiation of large phase III trials investigating immunomodulatory drugs for atherosclerosis, cardiovascular disease treatment enters a new era. We here propose a radically different approach: implementing and evaluating in vivo a combinatorial library of nanoparticles with distinct physiochemical properties and differential immune cell specificities. The library's nanoparticles are based on endogenous high-density lipoprotein, which can preferentially deliver therapeutic compounds to pathological macrophages in atherosclerosis. Using the apolipoprotein E-deficient (Apoe
Indexed as
ImmunotherapyAnimalsAnti-Inflammatory AgentsApolipoproteins EAtherosclerosisAutoradiographyBenzoatesBenzylaminesDisease Models, AnimalDrug Delivery SystemsFemaleGene Expression RegulationLipoproteins, HDLMacrophagesMiceMice, Inbred C57BLAnti-Inflammatory AgentsApolipoproteins EBenzoatesBenzylaminesGW 3965Lipoproteins, HDLRNA, Messengeratherosclerosisdrug deliveryimmunotherapymolecular imagingnanomedicine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.